Doxorubicin
is an anti-cancer chemotherapy drug. It is an intravenous injection through a
central or peripheral venous line. No pill form of this drug is available in
the market. Doxorubicin market is
expected to witness a significant growth in the developed regions due to the
multiple incidences of cancer occurrence in these regions. According to World
Health Organization (WHO), in 2012, 14.1 million new cancer cases were detected
worldwide.
Doxorubicin
is an anthracycline chemotherapy drug that slows down the growth of cancer
cells which is one of the primary reasons of its demand globally.. Four most
common cancers worldwide are lung cancer, prostate cancer, female breast and
bowel. Doxorubicin drug provides chemotherapy treatment for all four cancers
which is anticipated to drive the industry in next eight years. Early diagnosis
led to the longer duration of treatment which in turn increases the demand for
doxorubicin drug. Increasing effectiveness of drug therapies are contributing
to the higher spending on drugs for cancer care. Moreover, various government
initiatives for controlling cancer and increasing its awareness through
governmental organizations such as Cancer Prevention And Control Research
Network (CPCRN )and National Cancer Institute is creating to have a positive
impact on the anti-cancer drug. Increased alcohol consumption, usage of tobacco
coupled with lack of physical activity and unhealthy diet are considered to be
main risk factors of cancer worldwide. According to WHO estimates, the
mortality rate worldwide was 8.2 billion in 2012 and is expected to rise by
about 70% in the near future. Due to aforementioned reasons, anti-cancer drug
market revenues are anticipated to increase in the near future.
Browse Details of Report @ https://www.hexaresearch.com/upcoming-research/doxorubicin-market
Media
is also playing an important role in spreading awareness about various diseases
and related drugs. Consumer awareness of these drugs is expected to have a
positive impact on the doxorubicin market. Support from non-profit
organizations and regional government in UK on approval of drugs is anticipated
to drive the market during the forecast period.
However,
Doxorubicin therapy can cause a risk of developing leukemia and tumor lysis
syndrome which can further lead to kidney failure is expected to act as a
roadblock for the growth of doxorubicin market. This drug also has adverse
effects and can cause skin rashes, itchy sensation, can lead patient feel short
of breath, swelling of face, feeling dizzy and stomach ache. Moreover, it can
cause extensive tissue damage and can develop dizziness among consumer. High
treatment cost poses a challenge to this market. Also, pharmaceutical
industries significantly rely on the R&D initiatives. Pharmaceutical
agencies are focusing on new medicines in order to cater to the customer needs
which may poses as a threat to this market in the long run.
The
market can be segmented on the basis of cancer type. Doxorubicin treats number
of cancers such as acute lymphoblastic leukemia, acute myeloblastic leukemia,
bone sarcoma, breast cancer, endometrial cancer, gastric cancer, head and neck
cancer, liver cancer, kidney cancer, ovarion cancer, small cell lung cancer,
thyroid cancer and transitional cell bladder cancer. Drug used for treating
thyroid cancer dominated the market in the recent past on account of growing
incidences of thyroid cancer especially in UK.
The
U.S. dominated the market in the near past on account approval of doxorubicin
products by FDA and increasing number of cancer incidences. Europe is one of
the major markets owing to increasing number of deaths due to cancer. Emerging
nations such as India and China are anticipated to show a substantial growth
rate based on the growing population, cancer incidences and tobacco
consumption. Africa is expected to observe a lower growth rate owing to lack of
consumer awareness and healthcare infrastructure, and expensive medication.
Key
players in this market include Pfizer Inc., Dabur Pharmaceuticals Ltd., Cadila
Pharmaceuticals Ltd., German Remedies Ltd., Biological E Ltd., Elder
Pharmaceuticals Pvt. Ltd., Cipla Ltd., Sun Pharmaceuticals Industries Ltd.,
Natco Pharma Ltd., Biochem Pharmaceutical Industries Ltd., Pharmacia India
Ltd., VHB Life Science Inc., Chandra Bhagat Pharma Pvt. Ltd., GLS Pharma Ltd.,
and Intas Laboratories Pvt. Ltd. Mergers and acquisitions in this industry is
helping acquirer in building technical expertise and hold a library of patents.
In
March 2015, Sun Pharmaceuticals Industries Ltd. acquired Ranbaxy Laboratories
Ltd. to increase its presence in the global and domestic markets by filling
therapeutic gaps in the U.S.
In
February 2013, Sun Pharma’s Lipodox (doxorubicin hydrochloride liposome
injection) was approved by FDA for the treatment of ovarian cancer in the
patients.
Browse Related Category Market
Reports@
About
Us:
Hexa Research is a market
research and consulting organization, offering industry reports, custom
research and consulting services to a host of key industries across the globe.
We offer comprehensive business intelligence in the form of industry reports
which help our clients obtain clarity about their business environment and
enable them to undertake strategic growth initiatives.
Contact
Us:
Ryan Shaw
Hexa Research
Felton Office Plaza
6265 Highway 9
Felton, California 95018
United States
Phone: +1-800-489-3075
Email:
sales@hexaresearch.com
Website - http://www.hexaresearch.com/
Follow us on Linkedin: https://www.linkedin.com/company/hexa-research
